CG Oncology, Inc. (CGON) AI Stock Analysis

• Market Cap: $3.23B
• Dividend Yield: N/A
• Average Volume (3M): 883.13K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: 217.84%
• EPS Growth: -85.53%
• Country: US
• Employees: 113
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 80,666,176
• 10 Day Avg. Volume: 951,814
• 30 Day Avg. Volume: 883,134
• PEG Ratio: -0.53
• Price to Book (P/B): 2.44
• Price to Sales (P/S): 1573.67
• P/FCF Ratio: -22.70
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 1.11K
• Enterprise Value/Gross Profit: 5.48K
• Enterprise Value/Ebitda: -14.66
• 1Y Price Target: $71.00
• Price Target Upside: 77.15% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): -2.18
• Revenue Forecast (FY): $2.77M

• Rating: 58 Neutral
• Price Target: $45.00 ▲(12.28% Upside)

CG Oncology, Inc. shows potential due to promising clinical trial results and a strong equity base. However, financial challenges, including no revenue and reliance on external funding, weigh heavily on the score. The positive technical indicators and strategic positioning in a lucrative market provide some optimism.

Positive Factors

Promising Clinical Trial Results

Successful clinical trials enhance CG Oncology's potential to secure regulatory approval and market entry, strengthening its competitive position in cancer therapy.

Strong Cash Position

A robust cash reserve provides financial stability and supports ongoing R&D and operational activities, reducing reliance on external funding.

Strategic Board Appointment

New leadership can bring fresh perspectives and strategic insights, potentially enhancing governance and decision-making processes.

Negative Factors

No Current Revenue

Lack of revenue generation poses a risk to financial sustainability, emphasizing the need for successful commercialization of products.

Significant Cash Burn

High cash burn rate can deplete reserves quickly, necessitating efficient cash management and successful product launches to ensure long-term viability.

Reliance on External Funding

Dependence on external funding can be risky if market conditions change, highlighting the importance of achieving operational self-sufficiency.

CG Oncology, Inc. Business Overview & Revenue Model

Company Description

CG Oncology, Inc. (CGON) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company primarily operates in the biopharmaceutical sector, specializing in the research and commercialization of novel cancer treatments that aim to improve patient outcomes. CGON's core product offerings include therapeutic candidates that target specific cancers, utilizing advanced drug delivery systems and proprietary technologies.

How the Company Makes Money

CG Oncology generates revenue primarily through the development and commercialization of its cancer therapies. The company may receive funding through partnerships and collaborations with larger pharmaceutical firms, which often involve milestone payments and royalties on future sales of approved products. Additionally, CGON may obtain revenue from government grants or research funding aimed at advancing its clinical trials. As the company progresses through the stages of drug development, it has the potential to generate significant earnings from product sales once its therapies are approved by regulatory bodies and launched into the market.

CG Oncology, Inc. Financial Statement Overview

Summary

CG Oncology, Inc. is facing financial challenges typical of early-stage biotechnology firms, with no current revenue and significant operating losses. The strong equity position and cash reserves provide some stability, but the reliance on external funding indicates potential risks if capital markets shift. The company’s focus should be on achieving revenue growth and improving operational efficiencies to sustain long-term viability.

Income Statement

CG Oncology, Inc. reported zero revenue in the latest year, indicating challenges in generating income. The company has experienced consistent losses with deteriorating EBIT and EBITDA margins, reflecting operational inefficiencies and potential barriers in monetizing its biotechnology developments.

Balance Sheet

The company's strong equity base relative to total assets, demonstrated by a high equity ratio, provides a solid financial foundation. However, the minimal debt levels and high cash reserves suggest limited leverage but also an underutilization of potential financing for growth.

Cash Flow

The negative free cash flow and significant negative operating cash flow highlight ongoing cash burn issues. Despite substantial financing inflows, the company is heavily reliant on external funding for operations, which could pose risks if such funding diminishes.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.17M	1.14M	204.00K	191.00K	10.36M
Gross Profit	441.00K	1.14M	204.00K	176.00K	10.35M
EBITDA	-164.89M	-114.63M	-55.43M	-35.23M	-12.38M
Net Income	-151.48M	-88.04M	-48.61M	-35.44M	-12.84M
Balance Sheet
Total Assets	729.91M	754.80M	199.30M	147.75M	58.69M
Cash, Cash Equivalents and Short-Term Investments	680.26M	742.00M	187.67M	143.48M	53.61M
Total Debt	7.24M	238.00K	1.03M	15.94M	15.13M
Total Liabilities	42.27M	21.42M	14.51M	22.57M	18.44M
Stockholders Equity	687.64M	733.38M	184.79M	125.18M	40.25M
Cash Flow
Free Cash Flow	-117.13M	-78.95M	-45.68M	-29.82M	-13.75M
Operating Cash Flow	-116.79M	-78.71M	-45.68M	-29.80M	-13.65M
Investing Cash Flow	-159.41M	-300.76M	-121.19M	-55.35M	-97.00K
Financing Cash Flow	277.94M	628.28M	87.00M	119.69M	15.45M

CG Oncology, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 40.08
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGON, the sentiment is Positive. The current price of 40.08 is below the 20-day moving average (MA) of 41.57, below the 50-day MA of 41.60, and above the 200-day MA of 31.03, indicating a neutral trend. The MACD of -0.72 indicates Positive momentum. The RSI at 47.01 is Neutral, neither overbought nor oversold. The STOCH value of 45.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CGON.

CG Oncology, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARQT	60 Neutral	$3.66B	-82.68	-28.17%	―	129.21%	80.35%
CGON	58 Neutral	$3.23B	-20.19	-24.74%	―	217.84%	-85.53%
BEAM	58 Neutral	$2.83B	-6.26	-47.19%	―	-84.07%	-157.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDYA	50 Neutral	$3.11B	-19.09	-14.15%	―	5376.27%	20.97%
IRON	43 Neutral	$3.00B	-14.90	-34.78%	―	―	-34.96%
COGT	37 Underperform	$5.98B	-16.95	-95.40%	―	―	4.32%

CG Oncology, Inc. Corporate Events

CG Oncology Appoints Christina Rossi to Board

On November 22, 2025, CG Oncology, Inc. announced the appointment of Christina Rossi to its Board of Directors, effective November 24, 2025. Rossi will serve as a Class II director with a term expiring at the 2026 annual meeting of stockholders, receiving a $45,000 annual fee and stock options. Concurrently, Simone Song resigned from the Board, effective immediately, with no disagreements cited with the company.

CG Oncology Appoints Jim DeTore as Interim CFO

On November 10, 2025, Robert Lapetina resigned as interim principal financial and accounting officer of CG Oncology, Inc., effective November 30, 2025. Subsequently, on November 14, 2025, the company appointed Jim DeTore as the new interim principal financial and accounting officer, effective November 17, 2025. DeTore’s appointment comes through a consulting agreement with Monomoy Advisors, LLC, which stipulates a monthly payment structure and an initial engagement term of three months, with an option to extend. This leadership change is significant for CG Oncology as it navigates its financial and accounting operations, potentially impacting its strategic direction and stakeholder relations.

CG Oncology Highlights Drug Potential at Healthcare Conference

CG Oncology, Inc. presented an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025, highlighting the potential of their investigational drug, cretostimogene grenadenorepvec, in treating bladder cancer. The presentation emphasized promising clinical trial results, including high response rates and a favorable safety profile, positioning the company to capitalize on a multi-billion dollar market opportunity in non-muscle invasive bladder cancer (NMIBC).